Emerging Therapeutics for Patients with Triple-Negative Breast Cancer.
Auteurs : Agostinetto E, Eiger D, Punie K, de Azambuja E Jaar : 2021 Journal : Curr Oncol Rep
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).
Auteurs : Moreno-Aspitia A, Holmes EM, Jackisch C, de Azambuja E, Boyle F, Hillman DW, Korde L, Fumagalli D, Izquierdo MA, McCullough AE, Wolff AC, Pritchard KI, Untch M, Guillaume S, Ewer MS, Shao Z, Sim SH, Aziz Z, Demetriou G, Mehta AO, Andersson M, Toi M, Lang I, Xu B, Smith IE, Barrios CH, Baselga J, Gelber Rd, Piccart-Gebhart M Jaar : 2021 Journal : Eur J Cancer
The Exciting New Field of HER2-Low Breast Cancer Treatment.
Auteurs : Eiger D, Agostinetto E, Saúde-Conde R, de Azambuja E Jaar : 2021 Journal : Cancers (Basel)
Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience.
Auteurs : Franzoi MA, Saúde-Conde R, Ferreira SC, Eiger D, Awada A, de Azambuja E Jaar : 2021 Journal : Breast
Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer.
Auteurs : Franzoi MA, Agostinetto E, Perachino M, Del Mastro L, de Azambuja E, Vaz-Luis I, Partridge AH, Lambertini M Jaar : 2021 Journal : Lancet Oncol